Clinical efficacy analysis of 110 cases of childhood vitiligo with non-surgical combined therapy

Abstract Background Vitiligo has a negative effect on children’s physical and psychological health. Few studies have examined long-term treatment efficacy for childhood vitiligo. Therefore, we evaluated the long-term effectiveness of non-surgical combination therapy in pediatric patients with vitiligo and analyzed factors that affect its efficacy. Methods Pediatric patients (⩽12 years) with vitiligo who were treated with topical corticosteroids/topical calcineurin inhibitors and phototherapy for 12 months were retrospectively studied. Short-term systemic corticosteroids were administered according to individual clinical conditions. All lesions were photographed to assess repigmentation at 3-month intervals. Clinical data, the treatment effectiveness, and factors affecting the therapeutic effect were analyzed. Results Overall, 110 children (51 [53.6%] girls; mean [SD] age, 7.1 ± 3.0 years; 104 [94.5%] with activity status) were treated for a mean period of 23.13 ± 14.03 months (range, 5–86 months). The overall >50% repigmentation rate was 64.5%. A longer duration of treatment was associated with a higher repigmentation rate (X 2 trend = 36.229, P < .001). The vitiligo disease activity score at the first visit was positively correlated with the overall repigmentation rate (rs = 0.301, P = .001). Conclusions Treatment lasting longer than 1 year is recommended in children with vitiligo. The best repigmentation effect can be achieved by combination therapy in the rapid progression stage.

[1]  Ji-Yuan Wu,et al.  Consensus on the Diagnosis and Treatment of Vitiligo in China (2021 Revision)# , 2021 .

[2]  Baofeng Guo,et al.  The effects of tacrolimus plus phototherapy in the treatment of vitiligo: a meta-analysis , 2020, Archives of Dermatological Research.

[3]  I. Majid,et al.  Excimer light therapy in childhood segmental vitiligo: Early treatment gives better results , 2020, Dermatologic therapy.

[4]  A. Vojvodić,et al.  Emerging drugs for the treatment of vitiligo , 2020, Expert opinion on emerging drugs.

[5]  J. Seneschal,et al.  Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells , 2019, Experimental dermatology.

[6]  S. Khandpur,et al.  What Is New in Narrow-Band Ultraviolet-B Therapy for Vitiligo? , 2019, Indian dermatology online journal.

[7]  R. Gniadecki,et al.  Prescribing Home Narrowband UVB Phototherapy: A Review of Current Approaches , 2018, Journal of cutaneous medicine and surgery.

[8]  D. Rigopoulos,et al.  Childhood Vitiligo , 2019, American Journal of Clinical Dermatology.

[9]  A. Bishnoi,et al.  Clinical and Molecular Aspects of Vitiligo Treatments , 2018, International journal of molecular sciences.

[10]  T. Thng,et al.  Treatment outcomes of vitiligo in Asian children , 2018, Pediatric dermatology.

[11]  U. Wollina,et al.  Vitiligo in Children: A Better Understanding of the Disease , 2018, Open access Macedonian journal of medical sciences.

[12]  Hong-Duo Chen,et al.  Comprehensive survey of vitiligo patients in the northeast of China using a predesigned questionnaire , 2018, The Journal of dermatology.

[13]  T. Mohammad,et al.  The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo , 2017, Journal of the American Academy of Dermatology.

[14]  K. Ezzedine,et al.  A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children , 2016, Pediatrics.

[15]  N. Silverberg,et al.  Current Management of Pediatric Vitiligo , 2015, Pediatric Drugs.

[16]  P. Bahadoran,et al.  Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. , 2015, The Journal of investigative dermatology.

[17]  D. Parsad,et al.  Low-Dose Oral Mini-Pulse Dexamethasone Therapy in Progressive Unstable Vitiligo , 2013, Journal of cutaneous medicine and surgery.

[18]  Jun-Mo Yang,et al.  The effectiveness of early treatment in segmental vitiligo: retrospective study according to disease duration , 2013, Photodermatology, photoimmunology & photomedicine.

[19]  I. Majid,et al.  Relapse After Methylprednisolone Oral Minipulse Therapy in Childhood Vitiligo: A 12-Month Follow-Up Study , 2013, Indian journal of dermatology.

[20]  M. Picardo,et al.  Guidelines for the management of vitiligo: the European Dermatology Forum consensus , 2013, The British journal of dermatology.

[21]  D. Khan,et al.  CHILDHOOD VITILIGO: RESPONSE TO METHYLPREDNISOLONE ORAL MINIPULSE THERAPY AND TOPICAL FLUTICASONE COMBINATION , 2009, Indian journal of dermatology.

[22]  N. Rath,et al.  An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad / narrow band UVB phototherapy in progressive vitiligo. , 2008, Indian journal of dermatology, venereology and leprology.

[23]  H. Hönigsmann,et al.  Oral dexamethasone pulse treatment for vitiligo. , 2001, Journal of the American Academy of Dermatology.

[24]  Soo Min Kim,et al.  The efficacy of low‐dose oral corticosteroids in the treatment of vitiligo patients , 1999, International journal of dermatology.

[25]  W. Westerhof,et al.  Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. , 1999, Archives of dermatology.